Preview

Научно-практическая ревматология

Расширенный поиск

Вакцинация у больных системной красной волчанкой: результаты и перспективы

https://doi.org/10.14412/1995-4484-2018-373-379

Полный текст:

Аннотация

В ревматологии значимость коморбидных инфекций за последнее время существенно увеличилась, особенно в связи с внедрением в клиническую практику генно-инженерных биологических препаратов. Одним из путей решения указанной проблемы является изучение и активное применение вакцин. В настоящем обзоре рассмотрены вопросы, касающиеся применения вакцин против различных инфекций у больных системной красной волчанкой. Обсуждаются безопасность и иммуногенность вакцинации, в том числе с применением адъювантных вакцин. Обозначены основные направления будущих исследований по рассматриваемой проблеме.

Об авторах

Б. С. Белов
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
115522, Москва, Каширское шоссе, 34А


С. К. Соловьев
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
115522, Москва, Каширское шоссе, 34А


Г. М. Тарасова
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
115522, Москва, Каширское шоссе, 34А


Е. А. Асеева
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
115522, Москва, Каширское шоссе, 34А


Список литературы

1. Ющук НД, Венгеров ЮА, редакторы. Инфекционные болезни: Национальное руководство. Москва: ГЭОТАР-Медиа; 2009. 1056 с. [Yushchuk ND, Vengerov YuA, editors. Infekcionnye bolezni: Nacional'noe rukovodstvo [Infectious Diseases: National Guidelance]. Moscow: GEHOTAR-Media; 2009. 1056 p. (In Russ.)].

2. Tektonidou MG, Lewandowski LB, Hu J, et al. Survival in adults and children with systemic lupus erythematosus: a systematic review and Bayesian meta-analysis of studies from 1950 to 2016. Ann Rheum Dis. 2017 Dec;76(12):2009-16. doi: 10.1136/annrheumdis-2017-211663

3. Левицки А, Линдер С, ван Волленховен РФ. Ритуксимаб в терапии системной красной волчанки. Научно-практическая ревматология. 2013;51(3):223-39 [Levitsky A, Linder S, van Vollenhoven RF. Rituximab in the management of systemic lupus erythematosus. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2013;51(3):223-39 (In Russ.)].

4. Merrill JT, Ginzler EM, Wallace DJ, et al. Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus. Arthritis Rheum. 2012 Oct;64(10):3364-73. doi: 10.1002/art.34564

5. Van Assen S, Agmon-Levin N, Elkayam O, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2011;70(3):414- 22. doi: 10.1136/ard.2010.137216

6. Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheum. 2016;68(1):1-26. doi: 10.1002/art.39480

7. Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3):e44-100. doi: 10.1093/cid/cit684

8. Krasselt M, Baerwald C, Seifert O. Insufficient vaccination rates in patients with systemic lupus erythematosus in a German outpatient clinic. Z Rheumatol. 2017 Dec 13. doi: 10.1007/s00393-017-0410-5

9. Lawson EF, Trupin L, von Scheven E, et al. Reasons for failure to obtain influenza and pneumococcal vaccines among immunosuppressed individuals with systemic lupus erythematosus. Arthritis Rheum. 2013;65(10 Suppl):362.

10. Ditto MC, Batticiotto A, Gerardi MC, et al. Reasons Why Patients Failed Vaccinations Vs Influenza and Pneumococcus. Monocentric Cross-Sectional Study. Arthritis Rheum. 2017;69(Suppl 10):S396-7.

11. Wise K, Barbar-Smiley F, Lemle S, et al. Pre-Visit Planning Improves Pneumococcal Vaccination in Patients with ChildhoodOnset Systemic Lupus Erythematosus. Arthritis Rheum. 2017;69(Suppl 10):S2924-5.

12. Brocq O, Acquacalda E, Berthier F, et al. Influenza and pneumococcal vaccine coverage in 584 patients taking biological therapy for chronic inflammatory joint: A retrospective study. Joint Bone Spine. 2016;83(2):155-9. doi: 10.1016/j.jbspin.2015.11.005

13. Williams GW, Steinberg AD, Reinertsen JL, et al. Influenza immunization in systemic lupus erythematosus. A double-blind trial. Ann Intern Med. 1978;88(6):729-34. doi: 10.7326/0003-4819- 88-6-729

14. Brodman R, Gilfillan R, Glass D, Schur PH. Influenza vaccine response in systemic lupus erythematosus. Ann Intern Med. 1978;88(6):735-40. doi: 10.7326/0003-4819-88-6-735

15. Louie JS, Nies KM, Shoji KT, et al. Clinical and antibody responses after influenza immunization in systemic lupus erythematosus. Ann Intern Med. 1978;88(6):790-2. doi: 10.7326/0003- 4819-88-6-790

16. Ristow SC, Douglas RG Jr, Condemi JJ. Influenza vaccination of patients with systemic lupus erythematosus. Ann Intern Med. 1978;88(6):786-9. doi: 10.7326/0003-4819-88-6-786

17. Herron A, Dettleff G, Hixon B, et al. Influenza vaccination in patients with rheumatic diseases. Safety and efficacy. JAMA. 1979;242(1):53-6. doi: 10.1001/jama.1979.03300010037025

18. Abu-Shakra M, Zalmanson S, Neumann L, et al. Influenza virus vaccination of patients with systemic lupus erythematosus: effects on disease activity. J Rheumatol. 2000;27(7):1681-5.

19. Abu-Shakra M, Press J, Sukenik S, Buskila D. Influenza virus vaccination of patients with SLE: effects on generation of autoantibodies. Clin Rheumatol. 2002;21(5):369-72. doi: 10.1007/s100670200099

20. Abu-Shakra M, Press J, Varsano N, et al. Specific antibody response after influenza immunization in systemic lupus erythematosus. J Rheumatol. 2002;29(12):2555-7.

21. Kostianovsky A, Charles P, Alves JF, et al. Immunogenicity and safety of seasonal and 2009 pandemic A/H1N1 influenza vaccines for patients with autoimmune diseases: a prospective, monocentre trial on 199 patients. Clin Exp Rheumatol. 2012 Jan–Feb;30(1 Suppl 70):S83-9.

22. Huang Y, Wang H, Wan L, et al. Is Systemic Lupus Erythematosus Associated With a Declined Immunogenicity and Poor Safety of Influenza Vaccination?: A Systematic Review and Meta-Analysis. Medicine (Baltimore). 2016 May;95(19):e3637. doi: 10.1097/MD.0000000000003637

23. Puges M, Biscay P, Barnetche T, et al. Immunogenicity and impact on disease activity of influenza and pneumococcal vaccines in systemic lupus erythematosus: a systematic literature review and meta-analysis. Rheumatology (Oxford). 2016 Sep;55(9):1664-72. doi: 10.1093/rheumatology/kew211

24. Chang CC, Chang YS, Chen WS, et al. Effects of annual influenza vaccination on morbidity and mortality in patients with Systemic Lupus Erythematosus: A Nationwide Cohort Study. Sci Rep. 2016 Dec 2;6:37817. doi: 10.1038/srep37817

25. Luijten RK, Cuppen BV, Bijlsma JW, Derksen RH. Serious infections in systemic lupus erythematosus with a focus on pneumococcal infections. Lupus. 2014;23(14):1512-6. doi: 10.1177/0961203314543918

26. Schurder J, Goulenok T, Jouenne R, et al. Pneumococcal infection in patients with systemic lupus erythematosus. Joint Bone Spine. 2017 May 18. pii: S1297-319X(17)30103-3. doi: 10.1016/j.jbspin.2017.05.012

27. Pisoni C, Sarano J, Benchetrit G, et al. [Antipneumococcal vaccination in patient with systemic lupus erythematosus]. Medicina (B Aires). 2003;63(5):388-92.

28. Tarasova GM, Belov BS, Sergeeva MS, et al. Tolerability, efficacy and immunogenicity of 23-valent pneumococcal vaccine in sle patients. Ann Rheum Dis. 2017;76(Suppl 2):1226. doi: 10.1136/annrheumdis-2017-eular.2347

29. Centers for Disease Control and Prevention (CDC). Use of 13- valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2012;61:816-9.

30. Вакцинопрофилактика пневмококковой инфекции. Федеральные клинические рекомендации. Москва; 2015. 24 с. [Vakcinoprofilaktika pnevmokokkovoj infekcii. Federal'nye klinicheskie rekomendacii [Vaccine prophylaxis of pneumococcal infection. Federal Clinical Recommendations]. Moscow; 2015. 24 p. (In Russ.)].

31. Grabar S, Groh M, Bahuaud M, et al. Pneumococcal vaccination in patients with systemic lupus erythematosus: A multicenter placebo-controlled randomized double-blind study. Vaccine. 2017;35(37):4877-85. doi: 10.1016/j.vaccine.2017.07.094

32. Nagel J, Saxne T, Geborek P, et al. Treatment with belimumab in systemic lupus erythematosus does not impair antibody response to 13-valent pneumococcal conjugate vaccine. Lupus. 2017 Sep;26(10):1072-81. doi: 10.1177/0961203317695465

33. Chatham W, Chadha A, Fettiplace J, et al. A randomized, openlabel study to investigate the effect of belimumab on pneumococcal vaccination in patients with active, autoantibody-positive systemic lupus erythematosus. Lupus. 2017 Dec;26(14):1483-90. doi: 10.1177/0961203317703495

34. Mercado U. Why have rheumatologists been reluctant to vaccinate patients with systemic lupus erythematosus? J Rheumatol. 2006;33(8):1469-71.

35. Curtis JR, Yang S, Chen L, et al. Herpes zoster infection across auto-immune and inflammatory diseases: implications for vaccination. Ann Rheum Dis. 2014;73Suppl 2:452. doi: 10.1136/annrheumdis-2014-eular.5983

36. Chakravarty EF, Michaud K, Katz R, Wolfe F. Increased incidence of herpes zoster among patients with systemic lupus erythematosus. Lupus. 2013;22(3):238-44. doi: 10.1177/0961203312470186

37. Guthridge JM, Cogman A, Merrill JT, et al. Herpes zoster vaccination in SLE: a pilot study of immunogenicity. J Rheumatol. 2013 Nov;40(11):1875-80. doi: 10.3899/jrheum.130170

38. Hales CM, Harpaz R, Ortega-Sanchez I, et al. Update on recommendations for use of herpes zoster vaccine. MMWR Morb Mortal Wkly Rep. 2014;63(33):729-31.

39. Chakravarty EF. Incidence and Prevention of Herpes Zoster Reactivation in Patients with Autoimmune Diseases. Rheum Dis Clin North Am. 2017 Feb;43(1):111-21. doi: 10.1016/j.rdc.2016.09.010

40. Raposo A, Tani C, Costa J, Mosca M. Human papillomavirus infection and cervical lesions in rheumatic diseases: a systematic review. Acta Reumatol Port. 2016 Jul-Sep;41(3):184-90.

41. Klumb EM, Pinto AC, Jesus GR, et al. Are women with lupus at higher risk of HPV infection? Lupus. 2010;19(13):1485-91. doi: 10.1177/0961203310372952

42. Lyrio LD, Grassi MF, Santana IU, et al. Prevalence of cervical human papillomavirus infection in women with systemic lupus erythematosus. Rheumatol Int. 2013;33(2):335-40. doi: 10.1007/s00296-012-2426-0

43. Mok CC, Ho LY, Fong LS, To CH. Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study. Ann Rheum Dis. 2013;72(5):659-64. doi: 10.1136/annrheumdis-2012-201393

44. Moraes-Fontes MF, Antunes AM, Gruner H, Riso N. Vaccination of Adult Patients with Systemic Lupus Erythematosus in Portugal. Int J Rheumatol. 2016;2016:2845617. doi: 10.1155/2016/2845617

45. Mathian A, Arnaud L, Adoue D, et al. [Prevention of infections in adults and adolescents with systemic lupus erythematosus: Guidelines for the clinical practice based on the literature and expert opinion]. Rev Med Interne. 2016;37(5):307-20. doi: 10.1016/j.revmed.2016.01.005

46. Kuruma KA, Borba EF, Lopes MH, et al. Safety and efficacy of hepatitis B vaccine in systemic lupus erythematosus. Lupus. 2007;16(5):350-4. doi: 10.1177/0961203307078225

47. Kashef S, Ghazizadeh F, Derakhshan A, et al. Antigen-specific antibody response in juvenile-onset SLE patients following routine immunization with tetanus toxoid. Iran J Immunol. 2008 Sep;5(3):181-4. doi: IJIv5i3A7

48. Battafarano DF, Battafarano NJ, Larsen L, et al. Antigen-specific antibody responses in lupus patients following immunization. Arthritis Rheum. 1998 Oct;41(10):1828-34. doi: 10.1002/1529- 0131(199810)41:103.0.CO;2-T

49. Grimaldi-Bensouda L, Le Guern V, Kone-Paut I, et al. The risk of systemic lupus erythematosus associated with vaccines: an international case-control study. Arthritis Rheum. 2014;66(6):1559-67. doi: 10.1002/art.38429

50. Grimaldi-Bensouda L, Rossignol M, Kone-Paut I, et al. Risk of autoimmune diseases and human papilloma virus (HPV) vaccines: Six years of case-referent surveillance. J Autoimmun. 2017 May;79:84-90. doi: 10.1016/j.jaut.2017.01.005

51. Pellegrini M, Nicolay U, Lindert K, et al. MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database. Vaccine. 2009;27(49):6959-65. doi: 10.1016/j.vaccine.2009.08.101


Для цитирования:


Белов Б.С., Соловьев С.К., Тарасова Г.М., Асеева Е.А. Вакцинация у больных системной красной волчанкой: результаты и перспективы. Научно-практическая ревматология. 2018;56(3):373-379. https://doi.org/10.14412/1995-4484-2018-373-379

For citation:


Belov B.S., Solovyev S.K., Tarasova G.M., Aseeva E.A. VACCINATION IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS AND PROSPECTS. Rheumatology Science and Practice. 2018;56(3):373-379. (In Russ.) https://doi.org/10.14412/1995-4484-2018-373-379

Просмотров: 336


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-4484 (Print)
ISSN 1995-4492 (Online)